产品说明书

(+)-JQ1

Print
Chemical Structure| 1268524-70-4 同义名 : -
CAS号 : 1268524-70-4
货号 : A529842
分子式 : C23H25ClN4O2S
纯度 : 98%
分子量 : 456.988
MDL号 : MFCD22683748
存储条件:

粉末 Sealed in dry,2-8°C

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 45 mg/mL(98.47 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方:

IP 2% DMSO+2% Tween80+40% PEG300+water 6 mg/mL clear

PO 0.5% CMC-Na 45 mg/mL suspension

生物活性
靶点
  • BET

    BRD4 (1), IC50:77 nM

    BRD4 (2), IC50:33 nM

描述 BRDs (bromodomains) of human proteome can recognize the relaxed chromatin segments and bind to the acetylated nucleosomes, transcription factors and co-activators. (+)-JQ1 is a potent and selective bromodomain inhibitor with IC50 values of 77nM, 33nM and >10uM for BRD4(1), BRD4(2) and CREBBP, respectively[1]. The (+)-JQ-1-specific inhibition of BRDs can affect the production of the targeted transcription factor-dependent protein, including NRF2-dependent HO-1, NADPH:quinone oxidoreductase-1 as well as GCLC, SOCS3, STAT5-mediated regulation of target genes, RUNX3, SIRT1, MYC and its downstream target genes, etc.[2]. JQ1 can induce the differentiation and growth arrest in NUT midline carcinoma. Treatment with (+)-JQ-1, 250nM for 48h, potently decreased the expression of both BRD4 target genes, RAD21 and RAN, in NMC cells. Treatment with JQ1, i.p., 50mg/kg for 18 days, can regress the tumor growth and prolong overall survival of NMC797 xenografted mice. In addition, (-)-JQ-1 is the negative control compound of (+)-JQ-1[1].
作用机制 JQ1 can bind lysine acetylation binding site of BET bromodomains competitively with chromatin in a cellular environment.[1]
细胞研究
细胞系 浓度 检测类型 检测时间 活动说明 数据源
148I Growth Inhibition Assay 72 h IC50=0.284±0.035 μM 25944566
148I 0.25/0.5/1.0 μM Apoptosis Assay 24 h increases levels of cleaved caspase-3  25944566
148I 1 μM Apoptosis Assay 48 h induces cell apoptosis significantly 25944566
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.19mL

0.44mL

0.22mL

10.94mL

2.19mL

1.09mL

21.88mL

4.38mL

2.19mL

参考文献

[1]Filippakopoulos P, Qi J, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067-73.

[2]Shin DG, Bayarsaihan D. A Novel Epi-drug Therapy Based on the Suppression of BET Family Epigenetic Readers. Yale J Biol Med. 2017;90(1):63-71.